BACKGROUND: High-grade upper tract urothelial carcinoma (UTUC) is frequently upstaged after surgery and is associated with uniformly poor survival. Neoadjuvant chemotherapy may offer a way to improve clinical outcomes. The authors compared the survival rates of patients with UTUC who received neoadjuvant chemotherapy before surgery with the rates among patients who did not. METHODS: A retrospective review was conducted of patients with high-risk UTUC who received neoadjuvant chemotherapy followed by surgery from 2004 to 2008 (study group) compared with a matched cohort who underwent initial surgery from 1993 to 2003 (control group). Fisher exact tests, Wilcoxon rank-sum tests, and Kaplan-Meier methods were used. The log-rank test and Cox proportional-hazards models were used to evaluate the association of the 2 outcomes with patient, treatment, and tumor characteristics in univariate and multivariate models. RESULTS: Of 112 patients, there were 31 in the study group and 81 in the control group. Patients who received neoadjuvant chemotherapy had improved overall survival (OS) and disease-specific survival (DSS) with a 5-year DSS rate of 90.1% and a 5-year OS rate of 80.2% versus DSS and OS rates of 57.6% for those who underwent initial surgery (P 5.0204 and P 5.0015, respectively). In multivariate analyses, the neoadjuvant group had a lower risk of mortality (OS: hazard ratio, 0.42 [P 5.035]; DSS: hazard ratio, 0.19 [P 5.006]). CONCLUSIONS: Neoadjuvant chemotherapy improved the survival of patients with UTUC compared with a matched historic cohort of patients who underwent initial surgery. Patients with high-risk UTUC should be considered for neoadjuvant chemotherapy in view of the limited opportunity to administer effective cisplatin-based chemotherapy after nephroureterectomy. Cancer 2014;120:1794-9. V C 2014 American Cancer Society.
INTRODUCTION
The current standard treatment for upper tract urothelial carcinoma (UTUC) is radical nephroureterectomy. Results from single-institution, 1,2 multi-institution, 3 and population-based [4] [5] [6] studies have consistently demonstrated poor survival for patients with muscle-invasive and nonorgan-confined UTUC and for patients who have lymph node involvement identified after extirpative treatment. Initial support for the use of perioperative chemotherapy for UTUC was provided by studies of bladder cancer indicating improved survival in patients who received neoadjuvant, cisplatin-based chemotherapy. 7, 8 The strongest argument for the use of neoadjuvant, as opposed to adjuvant, chemotherapy in patients with UTUC is based on the high incidence of baseline and subsequent decline in renal function after nephroureterectomy. The use of adjuvant chemotherapy in this population is limited by the significant loss of renal function that occurs after surgery. Studies have demonstrated that >50% of patients who present with UTUC have chronic kidney disease, which worsens after nephroureterectomy and precludes postnephroureterectomy cisplatin-based chemotherapy in the majority of patients; indeed, only 19% to 22% of patients remain eligible for such therapy based on current renal function standards. 9, 10 We previously reported significant rates of disease downstaging and a 14% complete response rate after neoadjuvant chemotherapy among patients with high-risk UTUC who underwent nephroureterectomy compared with the rates for a matched historic control group of UTUC patients who underwent surgery without receiving neoadjuvant chemotherapy. 11 An earlier study by Igawa et al of 15 patients who had locally advanced UTUC produced a 13% complete remission rate and suggested improved survival. 12 The objective of the current study was to determine whether neoadjuvant chemotherapy confers a demonstrable survival benefit compared with initial surgery in patients with high-risk disease.
MATERIALS AND METHODS
On the basis of our finding that patient survival had not improved over several decades 1 and in light of the limitations of postoperative chemotherapy, in 2004, we began uniformly offering neoadjuvant chemotherapy to patients with UTUC who presented with high-risk features at our institution. The criteria used to identify high-risk UTUC patients to be considered for neoadjuvant chemotherapy were a biopsy specimen that exhibited high-grade tumor, [13] [14] [15] sessile tumor architecture, 16, 17 and large tumor burden (measurable on axial imaging). 18, 19 This became our standard practice based on the few retrospective studies available and expert opinion based on experience with urothelial cell carcinoma of the bladder. Patients who elect to undergo initial surgery despite the recommendation of neoadjuvant chemotherapy are not explicitly accounted for in the current analysis, but they form a very small proportion of the patients who are offered the neoadjuvant approach.
Thus, the study group comprised patients with UTUC who received neoadjuvant chemotherapy followed by radical nephroureterectomy at our institution from 2004 to 2008. These patients are the same as those in our initial report, 11 with the exception that only patients with clinically negative lymph node (cN0) status were included in the current analysis.
The control group consisted of patients with UTUC who underwent a nephroureterectomy at our institution from 1993 to2003, a period during which nephroureterectomy was offered to >90% of UTUC patients at our institution. 1 For the current retrospective study, we rereviewed the initial biopsy findings and included only those patients who had truly high-grade disease on the basis of the 2004 update to the World Health Organization tumor classification system, 20 and we also ensured that all patients had cN0 status.
For the current study, from the patients' records, we obtained and evaluated multiple clinical and pathologic features, including patient data (age, sex, Eastern Cooperative Oncology Group performance status), tumor data (laterality, radiographic tumor size, prior history of bladder cancer, location of tumor, tumor architecture), treatment (type and courses of neoadjuvant chemotherapy, lymphadenectomy performed), pathology (pathologic classification, pathologic lymph node classification, number of lymph nodes removed; and presence of extranodal extension, lymphovascular invasion, carcinoma in situ, and multifocality), and survival (disease-specific survival [DSS] and overall survival [OS] ). Pathologic complete remission was defined as the absence of any identifiable malignancy in all resected specimens. This retrospective study was approved by our institutional review board with waiver of informed consent.
The Fisher exact test and the Wilcoxon rank-sum test were used to compare categorical and continuous patient characteristics, respectively. The Kaplan-Meier method was used to estimate the probability of OS and DSS rates starting from surgery. Patients who were alive at the last followup or who were lost-to-follow-up or died for other reasons were censored. The log-rank test and a Cox proportionalhazards model were used to evaluate the association of these 2 time-to-event outcomes with patient characteristics, treatments, and tumor characteristics.
Clinically relevant variables and variables that were significant in univariate analysis were included in the multivariate model. Age, neoadjuvant chemotherapy, and sessile architecture were significant on univariate analysis for OS and/or DSS. The number of lymph nodes removed was added to the model as a surrogate to control differences over time in surgical management and principles of lymphadenectomy for upper tract disease. The mere performance of a lymphadenectomy as well as the total number of lymph nodes removed was not significantly associated with DSS or OS on univariate analysis. In a retrospective study, Roscigno et al recently reported that at least 8 lymph nodes were necessary to consider lymphadenectomy to be sufficient in patients with UTUC 21 ; therefore, we used this cutoff value in our analysis as a surrogate to account for differences in surgical technique. Lymphadenectomy in the study group included the paracaval or para-aortic lymph nodes with or without interaortocaval lymph nodes in those who had tumors above the mid-ureter; whereas patients who had distal ureteral tumors underwent pelvic lymphadenectomy. SAS software 9.3 (SAS Institute Inc., Cary, NC) and S Plus software 8.2 (TIBCO Software Inc., Palo Alto, Calif) were used for statistical analyses. P values < .05 were considered statistically significant.
RESULTS
The study group consisted of 31 patients who received neoadjuvant chemotherapy, and the control group consisted of 81 patients who underwent surgery without receiving neoadjuvant chemotherapy. Table 1 lists the results of baseline, surgical, and tumor characteristics of the 2 groups based on Fisher exact and Wilcoxon ranksum tests. Differences in laterality seemed spurious, and the lower incidence of lymphadenectomy in the control group reflects changing trends in treatment of the disease. Twenty patients (24.7%) in the control group received Neoadjuvant Chemo Improves UTUC Survival/Porten et al Cancer June 15, 2014 adjuvant chemotherapy; whereas, in the study group, none received adjuvant chemotherapy. There was no statistically difference (P 5 .416) in tumor size (mean 6 standard deviation) between 42 of 81 patients who underwent initial surgery (4.1 6 2.1 cm) and 19 of 31 patients who received neoadjuvant chemotherapy (3.7 6 1.3 cm).
Neoadjuvant therapy consisted of a cisplatincontaining regimen in 21 patients (standard or dose-dense methotrexate-vinblastine-doxorubicin-cisplatin, gemcitabine-cisplatin, or cisplatin-gemcitabine-ifosfamide) or high-dose ifosfamide-doxorubicin-gemcitabine in 3 patients. Kidney-sparing therapy (primarily gemcitabinepaclitaxel-doxorubicin) was received by 7 patients. All patients who were started on neoadjuvant chemotherapy were able to complete a median number of 4 cycles (interquartile range, 4-5 cycles; range, 2-6 cycles) before surgical extirpation. No patient was precluded from surgery because of preoperative chemotherapy.
Significant differences in disease staging were observed between the study population and the control group for individual stages and various stage subgroupings. For example, there were significantly lower rates of muscle-invasive disease (P 5 .0017) and organ-confined disease (P 5 .0024) in the study population versus the control group when evaluating only those who had pathologically lymph node-negative (pN0) disease (Table 2) . Downstaging remained significant when pN-positive patients were included (P 5 .0001 and P 5 .0005, respectively). There was no difference in the rates of pN1/pN2 disease between the control group and the study groups (18.5% and 6.5%, respectively; P 5 .2218). The 5-year OS and DSS rates were 80.2% and 90.1%, respectively, in the neoadjuvant group versus 57.6% and 57.6%, respectively, in the initial surgery group (Figs. 1, 2) .
Multivariate analyses were performed to assess the effects of individual factors on outcomes. Variables that were significant and clinically relevant in univariate analyses were included in multivariate models, as described above (see Materials and Methods). Cox regression Original Article models for OS indicated that neoadjuvant chemotherapy had a significant influence on OS (Table 3) . Age, the number of lymph nodes removed, and tumor architecture were not significant in the model. Similar analyses for DSS indicated the significant influence of neoadjuvant chemotherapy and tumor architecture (Table 3) .
DISCUSSION
Neoadjuvant chemotherapy was associated with improved OS and DSS compared with a matched historic cohort of patients who underwent initial surgery. Our results validate the initial observations reported by Igawa et al 12 and confirm the validity of using pathologic outcomes as a reasonable surrogate for outcomes in patients with UTUC. Prior studies demonstrated that the majority of patients with UTUC present with chronic kidney disease, and an even greater proportion cannot receive effective postoperative chemotherapy when adverse pathologic features are present. 9, 10 This finding may explain the conflicting and largely inconclusive reports from previous studies on the utility of adjuvant therapy for UTUC patients. [22] [23] [24] [25] [26] [27] Despite significant improvements in imaging and technologic advances in ureteroscopy (both presumably enabling earlier disease detection and treatment), not only have survival rates not improved for patients with UTUC, 1 but they may be worsening. 28 These developments indicate that the treatment paradigm for UTUC may need to shift from reflexive initial surgery to more accurate, thoughtful risk stratification with the consideration of neoadjuvant chemotherapy for patients who are classified as high risk.
Accurate clinical risk stratification becomes essential to avoid overtreatment and to identify the patients who are most likely to benefit from neoadjuvant chemotherapy. To aid with clinical risk stratification, it has been demonstrated in 2 preoperative nomograms that using a combination of various clinically available factors-such as biopsy grade, tumor architecture, results of selective cytology, and imaging findings like hydronephrosis-can provide independent prognostic value. 29, 30 These tools can help make the selection of the most appropriate treatment for a patient more systematic and more accurate than has historically been possible.
The limitations of the current study included the retrospective nature of the analysis. We performed pathologic reanalysis of any equivocal biopsy results and excluded those that indicated tumors that were not high grade. The survival rates for our control population were similar to the survival rates in other published studies of Likewise, in a study of 252 patients with UTUC who were treated surgically, Hall et al reported DSS rates from 72.6% to 40.5% for patients who had T2 through T4 disease. 2 Those data support the validity of our control population. In contrast to pathologic outcomes reported in bladder cancer neoadjuvant trials, documented downstaging for each individual patient with UTUC is not possible given the inaccuracy of initial clinical staging. It is believed that clinical stage has a misclassification bias of approximately 45%, and current expert opinion as well as many retrospective studies have demonstrated that tumor grade is a stronger predictor of high-risk disease with a strong association to advanced pathologic stage, recurrence, and outcome. 1, 3 Therefore, it is difficult to control for true clinical stage in this disease, which adds to the limitations of our findings and conclusions. In addition, a small number of patients did have a history of bladder cancer, and although this was not significantly different between groups, it may confound findings and outcomes related to DSS. Thus, matched historic cohorts like the group used in this study provide the best available data for assessing patient outcomes.
Nevertheless, only a prospective and, ideally, randomized study can definitively validate these findings. The design of such trials is made complicated by variations in the chemotherapy regimens needed, as observed in our study. Given the relatively advanced age of patients with UTUC and the high rates of comorbidity (including baseline renal dysfunction and cardiac disease), the current dogma of devising narrow inclusion criteria for the sake of study population homogeneity would render the recruitment of patients with this rare disease even more difficult, and the subsequent results would be inapplicable to a large proportion of patients. It is on this basis that a call has been made to consider in future trials more practical designs that allow for the diverse comorbidities frequently observed in patients with UTUC. In the meantime, the results of the current study provide a strong foundation for urologists and medical oncologists who seek to improve the outcomes of patients with UTUC to consider applying accurate clinical risk stratification and to offer neoadjuvant chemotherapy to patients with high-risk features.
Conclusions
Neoadjuvant chemotherapy in patients with high-risk UTUC resulted in significantly higher survival rates than surgery without neoadjuvant chemotherapy in a matched historic group.
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Introduction
Malignancies of the kidney and renal pelvis account for 3% to 5% of all solid adult cancers [1] . Despite the widespread use of abdominal cross-sectional imaging, which has led to a stage migration with earlier diagnosis of renal tumors, 25% to 30% of patients with renal cell carcinoma (RCC) present with metastatic disease [2] [3] [4] , and 10% of patients have tumor invasion into the inferior vena cava (IVC) at diagnosis [5] [6] [7] [8] . Less than 1% of patients have tumor thrombus extension above the level of the hepatic veins (level III and level IV) [9, 10] . Surgical extirpation remains the cornerstone of therapy for patients with RCC who have advanced IVC tumor thrombus extension [11] [12] [13] [14] . Even with advanced multidisciplinary management, major complications occur in one-third of patients [15, 16] . Surgical management is associated with a 5-year survival rate of 50% in patients with nonmetastatic disease in contemporary series [17] [18] [19] .
The strongest predictors of long-term survival in patients with high-level tumor thrombi include the presence of distant metastases, regional nodal metastases, and tumor pathologic characteristics including grade and necrosis [17] [18] [19] [20] [21] [22] [23] . Patients with level IV thrombus have a greater incidence of postoperative complications when compared with those with level III thrombus; however, tumor thrombus height (level III vs. level IV) has not been shown to be an independent predictor of long-term oncologic outcomes [15, 17] . Although pathologic features are the strongest predictors of long-term outcomes, these factors cannot be included in preoperative prognostic models owing to the infrequency of preoperative tissue diagnosis by biopsy in patients with RCC planned for nephrectomy and caval thrombectomy. Martinez-Salamanca et al. [24] reported a postoperative nomogram including pathologic variables for patients with all level thrombi (levels I-IV). Similarly, Nakayama et al. [25] reported on a preoperative prognostic model for patients with RCC who have venous thrombus; however, the study was small and included patients with lessadvanced thrombi (levels 0-II). There are currently no preoperative clinical tools to guide patient selection and counseling for surgical therapy specifically in the setting of RCC with suprahepatic tumor thrombus (levels III-IV). Thus, our aim was to develop multivariable models and prognostic nomograms for prediction of survival and major postsurgical complications based on readily available preoperative variables in patients with RCC who have advanced (levels III-IV) tumor thrombus. In addition to providing individualized risk assessment, these models could have utility in the design of future clinical trials of targeted therapies in this setting. (19 patients) . Tumor thrombus level was determined from transesophageal echocardiography or preoperative magnetic resonance imaging. Level III thrombus was defined as thrombus above the hepatic veins but below the diaphragm, and level IV thrombus was defined as thrombus extending above the diaphragm [9, 10] . Management including the use of preoperative targeted therapy, preoperative angioembolization, lymphadenectomy, and cardiopulmonary bypass was at the discretion of the surgical team. Follow-up was not standardized but commonly included physical examination, complete serum biochemistry, and computerized tomography or ultrasound every 3 months in the first year and semiannually thereafter.
Materials and methods
Institutional
Variables were determined by review of the medical records and included age, gender, race, body mass index, Eastern Cooperative Oncology Group (ECOG) performance status, the presence of systemic symptoms (weight loss, fatigue, and lower extremity swelling), clinical metastases at presentation, thrombus level, tumor size in centimeters, the use of preoperative tumor embolization, and cardiopulmonary bypass. Other variables included pathologic tumor stage, grade, presence of sarcomatoid differentiation, and histologic necrosis. Preoperative laboratory parameters included in the analysis were serum hematocrit, creatinine, alkaline phosphatase (ALP), and aspartate transaminase (AST) values.
Statistical analyses
The primary study end points were overall survival (OS) and occurrence of major complications (Clavien Z3A) within 90 days of surgery. A Cox proportional hazards model was used for the analysis of OS. Binary logistic regression was used for the major complications model. Variables were selected for the multivariable model if they could be determined preoperatively and reached a significance threshold of P o 0.05 on univariable analysis. Nomograms for prediction of 2-and 3-year survival and major complications (Clavien Z3A) were developed using regression coefficients from the multivariable analyses. The 2-year survival end point for the nomogram was selected, as this approximates the median follow-up of the cohort. Bootstrap validation (100 resamples) was performed, and calibration plots of observed vs. predicted probabilities were used to determine nomogram performance. Receiver operating characteristics and area under the curve analysis were performed to determine concordance index of the models. Nomogram development and calibration were performed with the RMS package of R software (version 3.0.1), and all the other statistical tests were conducted with SPSS (version 19, IBM, Armonk, NY).
Results
A total of 132 patients who underwent surgery for RCC with IVC tumor thrombus extending above the hepatic veins were identified. Clinicopathologic characteristics for the cohort are shown in Table 1 . Median age was 62 years (range: 24-84 y), and 83% of the cohort was male. Tumors were predominantly of clear cell histology (88.6%), and median tumor size was 10.6 cm (range: 3.5-29 cm). Tumor thrombus extended above the diaphragm (level IV) in 83 (63%) patients and above the hepatic veins but below the diaphragm (level III) in 49 (37%) patients. Overall, 23.5% of patients presented with distant metastases (Mþ). There were 6 (4.5%) patients who received preoperative targeted therapy, and preoperative angioembolization was used in 31 (23.5%) patients. A total of 52 (39.4 %) patients underwent cardiopulmonary bypass (4/49 with level III thrombus and 48/83 with level IV thrombus).
After a median follow-up of 24.5 months (range: 1-148 mo), there were 80 (60.6%) deaths (69 died of disease and 11 died of other causes). A total of 15 (11.4%) patients died within 90 days of surgery. The 5-year OS was 31.3% with a median OS of 19.3 months (95% CI: 8.6-30.0 mo). Median OS in M0 patients was 30.7 months (95% CI: 11.5-50.0) compared to 6.8 months (95% CI: 2.2-11.4) in Mþ patients. Prognostic factors for OS are shown in Table 2 . Multivariable analysis was performed with the inclusion of variables that could be determined preoperatively. Independent predictors of OS on multivariable analysis were ECOG performance status (hazard ratio ¼ 1.84, 95% CI: 1.39-2.44, P o 0.0001) and preoperative metastases (hazard ratio ¼ 2.52, 95% CI: 1.41-4.51, P ¼ 0.001).
Major complications within 90 days of surgery (Clavien Z3A) were reported in 46 patients (34.8%). The most common complications were respiratory related (11 patients, 8 .3%) including pleural effusion, respiratory failure, pulmonary edema, and pulmonary embolus. Cardiac complications including myocardial infarction, cardiac failure, and cardiac arrest occurred in 9 patients (6.8%). Postoperative hemorrhage was reported in 10 patients (7.6%), infectious complications in 5 patients (3.8%), and postoperative acute renal failure requiring hemodialysis in 7 patients (5.3%), and 4 (3.0%) patients developed prolonged ileus requiring parenteral nutrition. Prognostic factors predictive of major postsurgical complications within 90 days of surgery (Clavien Z3A) are shown in Table 3 . On univariable analysis, factors associated with an increased risk of major complications included preoperative systemic symptoms, level IV thrombus, elevated preoperative serum ALP levels, and elevated serum AST levels (Table 3) . On multivariable analyses, the presence of preoperative systemic symptoms was significantly associated with major complications (odds ratio ¼ 8.45, 95% CI: 2.68-26.62, P o 0.0001) ( Table 3) . We constructed preoperative nomograms for prediction of survival at 2 and 3 years ( Fig. 1A ) and for prediction of major complications within 90 days of surgery (Fig. 1B) . Preoperative variables were included in the nomogram if they achieved significance of P o 0.05 on univariate analysis. Nomogram calibration was performed with 100 bootstrap resamples and demonstrated that the models performed well when compared with an ideal model ( Figs. 2A and 3A) . The concordance index of the nomograms was 0.72 for 2-year survival prediction, 0.73 for 3-year survival, and 0.83 for major complication models (Figs. 2B and 3B).
Discussion
In this contemporary series of patients with RCC treated surgically for high-level tumor thrombus, approximately one-third of patients survived beyond 5 years, whereas a similar number of patients experienced a major postoperative complication (Clavien Z3A). Therefore, appropriate patient selection is paramount before proceeding with surgical resection, with the goal of identifying patients who are most likely to benefit from surgical resection. Several preoperative prognostic tools have been developed for the setting of localized and metastatic RCC [26, 27] , and postoperative prognostic models have been previously described for patients with levels I to IV thrombi [24, 25] . However, there are currently no tools for the preoperative prediction of outcomes of surgical resection specifically for patients with RCC who have high-level IVC tumor thrombus. In the current study, we have developed and internally validated a multivariable model for prediction of survival and major complications following surgery for RCC with level III/IV tumor thrombus. The models were constructed using only preoperative clinical variables with the aim that these prognostic tools would aid clinical decision making before surgical resection.
Clinical metastases at presentation and poor ECOG performance status were the strongest predictors of poor OS on multivariable analysis (Table 2) . Previous studies have demonstrated that patients with RCC who have advanced tumor thrombus and clinical metastases at presentation have dramatically inferior OS when compared with that of patients having nonmetastatic disease [17, 19, 25] . However, most patients in this study, as well as most of the patients in the literature, were treated in the pretargeted therapy era. We do not know what the survival of patients with metastatic RCC who have high-level venous tumor thrombus is in the targeted therapy era when appropriately selected for surgery or without surgery.
Although performance status has been shown to have an independent prognostic value in patients with metastatic RCC [28, 29] , prior studies of patients with IVC tumor thrombus have not demonstrated an independent association of ECOG performance status with OS [17, 19] . This can be explained by the inclusion of postoperative covariables into the analysis, such as pathologic features, which are the strongest determinants of prognosis. In our model, which incorporated only preoperative variables, higher ECOG status was strongly associated with worse OS (Table 2) .
Although we did not demonstrate a significant association of ECOG status with major complications, the presence of systemic symptoms (weight loss, fatigue, and lower extremity swelling), which may be a surrogate for systemic illness and performance status, was a strong predictor of major complications (Table 3) . Systemic symptoms have previously been shown to be associated with long-term cancerspecific survival in patients with RCC who do not have IVC thrombus [30] . Higher level of tumor thrombus (level IV vs. level III) was a significant predictor of major postoperative complications within 90 days of surgery on univariable analysis, and it trended to significance on multivariable analysis (Table 3) . Thrombus height was not associated with OS (Table 2) . Thus, despite the increased technical complexity of resection for level IV tumor thrombus, reflected in the higher incidence of major complications, the long-term oncologic outcomes for these patients are comparable to those for patients with level III thrombus. Elevated preoperative ALP and AST levels, which may reflect hepatic dysfunction owing to suprahepatic IVC obstruction, were associated with a greater risk of major complications and worse OS, although the associations trended toward significance after adjusting for covariates (Tables 2 and 3) . Preoperative angioembolization was performed in 23.5% of patients, but it was not associated with OS nor with major complications (Tables 2 and 3 ). Although preoperative angioambolization has been used for tumor shrinkage in some cases of large RCC or advanced tumor thrombus [31], our findings are consistent with previous studies that demonstrated no reduction of postoperative complications with preoperative embolization [32] . The decision to use cardiopulmonary bypass is sometimes made preoperatively and could be included in preoperative prognostic models. However, bypass was excluded from the nomogram, as the association of cardiopulmonary bypass with 90-day major complications only trended to significance on univariate analysis (Table 3) . Limitations of the study include the retrospective design and the lack of external validation. Management including tumor embolization, lymphadenectomy, use of bypass, and the surgical approach was not standardized and was based on clinical judgment. As our goal was to identify preoperative factors predictive of outcome, there were many intraoperative and postoperative variables such as lymphadenectomy and surgical technique that were not included in the model. Although serum albumin and lactate dehydrogenase values have previously been shown to be significant prognostic factors in advanced RCC [27] , we did not incorporate albumin and lactate dehydrogenase values into the model owing to incomplete data for these variables. We did not specifically address surgeon experience or learning curve, particularly as these complex surgical procedures were undertaken by skilled and experienced surgical oncologists at all centers. Tumor thrombus dislodgement was not specifically recorded as a complication; however, it is possible that some patients who developed clinical evidence of pulmonary embolus after surgery may have had dislodgement and embolization of tumor thrombus.
Bootstrap analysis was used for internal validation to address the limited sample size; however, external validation is required to determine general applicability of the model. The use of targeted therapies was variable, and only 4.5% of patients received neoadjuvant targeted therapies. However, targeted therapies are unlikely to provide a dramatic response in the presence of a large primary tumor and have been shown to be ineffective at reducing thrombus height in the preoperative setting [33] . Furthermore, the use of targeted therapies after surgery was not included. As most of the patients in this study were treated in the pretargeted therapy era, we do not know the survival for patients appropriately selected for surgery in the targeted therapy era.
Conclusions
Given the significant risk for postoperative complications following surgical resection for advanced caval tumor thrombus in patients with RCC, appropriate patient selection and counseling are paramount. The accurate preoperative models described in this study use easily determined clinical variables and basic laboratory investigations to predict major complications and survival for patients undergoing surgery for level III/IV tumor thrombus. These models are currently the only available tools specifically for risk assessment of patients with RCC who have highlevel (III/IV) IVC tumor thrombus. If externally validated, these tools may have value in preoperative counseling and future clinical trial design. [28] Current clinicopathological prognostic factors such as stage, grade and performance status provide important prognostic information. However, they lack the potential to incorporate the individual biological potential and predict clinical behavior of tumors. 4 Molecular markers have the capacity to interrogate biological heterogeneity of tumors and ultimately may help clinicians offer individualized treatment regimens. 4, 5 The most common mutations in cancer occur in cell cycle regulatory genes, potentially leading to uncontrolled tumor growth and progression. Elucidation of cell cycle pathways involved in carcinogenesis may lead to improvements in diagnosis, prognosis and management. Several studies have reported the prognostic role of cell cycle regulators in patients with urothelial, breast and adrenal cancers. 4,6e9 However, the prognostic role of cell cycle regulators and proliferative markers in RCC remains unclear.
Ki67, a marker of tumor proliferation, has been shown to be a prognostic marker in several neoplasms, including kidney cancer. 10 Increased Ki67 expression has been significantly associated with worse cancer specific survival in several studies. 11e13 We present, to our knowledge, the first known study evaluating the association of Cyclin D, Cyclin E, p16, p21, p27, p53, p57 and Ki67 expression with oncologic outcomes in a large cohort of patients with nonmetastatic (N0M0) clear cell RCC treated with extirpative therapy. In addition, we assess the feasibility of evaluating these markers in patients with N0M0 ccRCC.
MATERIALS AND METHODS
Patient Population/Evaluation
With approval of the institutional review board, 452 patients with nonmetastatic ccRCC treated with radical or partial nephrectomy between September 1997 and September 2010 were included in the study. We collected comprehensive clinical and pathological data and these were entered into an institutional review board approved database. Multiple data reviews and quality assurance checks were performed throughout the data collection process to ensure accuracy and completeness of data points. Followup consisted of physical examination, serum chemistry evaluation, liver function tests, chest radiography and abdominal computerized tomography, which were performed semiannually for the first 2 years and annually thereafter.
Specimen Evaluation
All pathological specimens were processed according to standard pathological procedures for diagnosis. All sections were retrieved and reviewed by a dedicated urological pathologist (PK) for confirmation of histopathological features and selection of 2 representative areas of the tumor for the construction of tissue microarray. Tissue microarrays were constructed from selected paraffin embedded ccRCC blocks for immunohistochemical evaluation. Using the 2004 WHO and the Fuhrman grading system we classified tumor histology and grade. 14, 15 Pathological stage was reassigned according to the 2010 American Joint Committee on Cancer TNM classification. 16 
Immunohistochemistry and Scoring
Standard immunohistochemistry staining procedure for Cyclin D, Cyclin E, p16, p21, p27, p53, p57 and Ki67 was performed using the Benchmark XT automated stainer (Ventana Medical Systems, Oro Valley, Arizona). Formalin fixed, paraffin embedded tissue sections were cut at 3 to 4 microns and air-dried overnight. The sections were deparaffinized, rehydrated and subjected to heat induced epitope retrieval. Sections were then incubated with appropriate primary antibody. For signal detection an ultraView universal detection system (Ventana) was used. The slides were developed using 3-3 0 -diaminobenzidine chromogen and counterstained with hematoxylin. Appropriate positive and negative controls were used for each run of immunostains.
The immunostains were evaluated by a genitourinary pathologist (PK) without knowledge of clinicopathological data. The dilutions for the immunostains were Cyclin D, Cyclin E, p16, p21 and p27: 1:40, 1:400, 1:2, 1:200 and 1:50, respectively. Ki67, p53, p57 were prediluted from the manufacturer. Typically mouse or rabbit monoclonal antibodies were used.
Only nuclear reactivity was considered positive. The extent of immunoexpression (0 to 100 percentage of cells staining) was assessed for each core. The average of the percentage of cells staining over the 2 cores from each case was used for further analysis. All markers were placed in the altered or normal category. Marker cutoffs were determined for statistical significance using Kaplan-Meier univariate analysis. Cyclin D immunoreactivity was considered altered when samples demonstrated less than 5% nuclear reactivity. Cyclin E and Ki67 were considered altered when samples demonstrated greater than 10% nuclear reactivity. p16, p21, p27, p53 and p57 were considered altered when samples had less than 1%, less than 5%, less than 2%, greater than 0.1%, less than 1.5%, respectively, of nuclear reactivity. Representative images of each marker are shown in figure 1 .
Using Kaplan-Meier univariate analysis, we assessed all combinations of the 8 markers to evaluate disease-free and cancer specific survival. Individuals with 1, 2, 3 or 4 marker alterations did not show any significant difference in DFS or CSS. A significantly statistical difference was seen in patients who had more than 4 altered markers. Thus, a prognostic marker score was defined as unfavorable if more than 4 biomarkers were altered.
Statistical Analysis
Fisher's exact test and the Pearson chi-square test were used to evaluate the association between molecular markers and with clinical and pathological characteristics.
Univariate recurrence and survival probabilities were estimated using the Kaplan-Meier method in nonmetastatic cases. Univariate and multivariate Cox regression models were used to analyze predictors of DFS and CSS. All variables for multivariate analysis were entered based on significance in univariate analysis and on clinical relevance. All reported p values are 2-sided and statistical significance was set at p <0.05. All statistical analyses were performed using SPSSÒ v19.
RESULTS
Patient Demographics and Clincopathological Findings
The clinical features of the entire cohort are summarized in table 1. The study included 452 patients, of which 277 were males (61%). The median age and followup for the entire cohort were 57 (range 17 to 85) years and 24 months (range 6 to 150), respectively. Median time to recurrence and death were 20 and 26 months (range 0 to 150). Extrarenal extension (pT3-T4) was seen in 120 (27%) patients and advanced grade (G3-4) in 169 (37%) patients. Regional nodal involvement and systemic metastases at nephrectomy were present in 22 (5%) and 51 (11%) patients, respectively. At the time of analysis, of 
DISCUSSION
Prognostic factors that accurately predict oncologic outcomes are necessary for robust clinical decision making. However, current prognostic factors such as pathological stage and grade have limited accuracy in predicting the outcomes of patients with localized RCC. Assessment of tissue biomarkers such as cell cycle regulators has the potential to clarify unique biological features that identify patients at high risk for adverse outcomes. 17, 18 The loss of regulated cell cycle progression typically leads to malignant cellular transformation and ultimately tumorigenesis. Under the regulation of promoters (Cyclin D and E) and CDK inhibitors (p16, p21, p27, p57), CDKs control the activity of cell cycle progression through the G1/S-phase into DNA synthesis. 19 In malignant tumors the unchecked and unbalanced control of CDKs and CDK inhibitors frequently leads to the malignant transformation of cells. 19, 20 The current panel of molecular markers elucidates the role of cell cycle regulators and the impact of their deregulation in patients with ccRCC.
The integration of cell cycle regulators to augment clinical decision making has been successfully used in multiple other malignancies. Recent studies in breast cancer show that the key biological drivers in 9 prognostic signatures are 4, 5, 22 Youssef et al demonstrated the significant role of a panel of cell cycle regulators in predicting oncologic outcomes in patients with squamous cell carcinoma of the bladder. 23 Others have shown the prognostic role of cell cycle regulators in improving staging and prognosis of patients with upper tract urothelial carcinoma. 24 Clinical integration of our marker panel into predicative models of recurrence and survival may aid in refining clinical decision making. For instance, patients with RCC with an unfavorable MS may require a more rigorous surveillance regimen than patients with a favorable MS. Additionally, integration of our marker panel could have a significant impact on the role of adjuvant therapies following extirpative therapy.
In this study we investigated the association of 8 biomarkers with DFS and CSS in 452 patients treated surgically with curative intent for localized ccRCC. Most patients had abnormal expression of at least 1 biomarker and unfavorable MS was present in 12.2%, highlighting the potential relevance of these alterations in ccRCC tumorigenesis. Furthermore, unfavorable MS was associated with features of aggressive disease and, consequently, of worse DFS and CSS.
Compared to single marker analysis, systematic interrogation of multiple molecules involved within a biologically relevant pathway provides enhanced assessment of the pathway's functional status. 25 Cumulative impact of the number of abnormally expressed cell cycle regulators has been demonstrated in patients with bladder cancer. 4e6,25e27 In several such studies a dose dependent relationship of the number of altered cell cycle biomarkers and oncologic outcomes of patients treated with cystectomy has been documented. 5, 26 Our data confirm a robust independent predictive value of a MS based on the number of altered cell cycle regulatory molecules in patients treated surgically for nonmetastatic ccRCC. 4, 5 Further addition of a proliferative marker to the current panel aids in determining the abnormal tumor cell proliferation and clinical behavior.
This study has several important limitations which center on the retrospective study design and potential associated bias. Furthermore, there is variability inherent to immunohistochemistry techniques used. We also acknowledge that variability exists throughout the specimen and that the 2 cores used to determine immunoexpression may not have been sufficient enough to fully capture biology of the whole specimen. Our median followup time was only 2 years, which could explain the lack of independent association of the marker score with CSS. We believe with a longer followup time, our CSS may be significant. Future studies will be needed to independently and prospectively validate our findings. Despite these limitations, our study is unique for several reasons. We chose to focus on a homogenous cohort of patients with nonmetastatic ccRCC. We also used systematic repeat analysis of all tissue specimens and standardized semiquantitative assessment of cell cycle expression, easily reproducible by most modern pathology laboratories. Furthermore, the 2 representative cores that were used to assess immunoexpression were areas that contained the highest grade or most invasive areas as determined by our pathologist. Lastly, to our knowledge, this is the first study evaluating the association between this unique panel of cell cycle regulators and the oncologic outcomes in patients with ccRCC.
CONCLUSIONS
In this study the cumulative number of altered cell cycle regulators and proliferative biomarkers correlated with aggressive pathological features and inferior oncologic outcomes in patients with ccRCC. Our findings support further prospective pathway based exploration of cell cycle and proliferative biomarkers to augment current clinicopathological predictors of oncologic outcomes in kidney cancer. 
Objective
To evaluate the effect of adjuvant chemotherapy (AC) on mortality after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) with positive lymph nodes (LNs) and to identify patient subgroups that are most likely to benefit from AC.
Patients and methods
We retrospectively analysed data of 263 patients with LNpositive UTUC, who underwent full surgical resection. In all, 107 patients (41%) received three to six cycles of AC, while 156 (59.3%) were treated with RNU alone. UTUC-related mortality was evaluated using competing-risks regression models.
Results
In all patients (T all N+), administration of AC had no significant impact on UTUC-related mortality on univariable (P = 0.49) and multivariable (P = 0.11) analysis. Further stratified analyses showed that only N+ patients with pT3-4 disease benefited from AC. In this subgroup, AC reduced UTUC-related mortality by 34% (P = 0.019). The absolute difference in mortality was 10% after the first year and increased to 23% after 5 years. On multivariable analysis, administration of AC was associated with significantly reduced UTUC-related mortality (subhazard ratio 0.67, P = 0.022). Limitations of this study are the retrospective non-randomised design, selection bias, absence of a central pathological review and different AC protocols.
Introduction
Upper tract urothelial carcinoma (UTUC) accounts for 5-10% of all UCs with an annual incidence of two cases per 100 000 inhabitants in Western countries [1] . Radical nephroureterectomy (RNU) with excision of the ipsilateral bladder cuff is the therapeutic standard of care, while conservative treatment is reserved for selected patients with low-risk disease or a solitary kidney [2] . The impact of a lymph node (LN) dissection during RNU on survival remains unclear, although positive LNs, the number of positive LNs and extranodal extension are all known adverse prognostic factors [3, 4] . During recent decades, only limited progress has been made in surgical techniques and systemic treatment of UTUC with survival outcomes remaining relatively poor [5] .
Data from randomised controlled trials in bladder cancer indicate that chemotherapy should be an integral part of the multimodal therapeutic concept for advanced UC [2] . In contrast, there is insufficient evidence to integrate neoadjuvant or adjuvant chemotherapy (AC) in the disease management scheme for advanced UTUC [6] . At present, chemotherapy is only recommended in the palliative setting for patients with metastatic disease [2] . Studies have shown that neoadjuvant cisplatin-based chemotherapy may play a role in down-staging and survival improvement of high-risk UTUC, even though a high inaccuracy of initial clinical staging hampers appropriate clinical risk stratification [7] . Similarly, data conflict regarding the use of AC in patients at a high risk of disease recurrence [8] . Most retrospective studies show no benefit of AC, but others have shown a positive impact on disease-free survival [9, 10] . Most of these studies included relatively few patients and none specifically evaluated patients at the highest risk of disease recurrence, i.e. those with positive LNs [11] .
The aim of the present study was to compare survival outcomes of patients with LN-positive UTUC treated with or without AC after RNU, and to identify patient subgroups that are most likely to benefit from AC.
Patients and Methods
We retrospectively queried the Institutional Review Boardapproved UTUC databases of five academic urology centres. These databases contain data of 1 461 consecutive patients, who underwent between 1987 and 2012 RNU with a LN dissection, based on the surgical report. Patients with LNpositive UTUC without evidence of distant metastases at the time of RNU were eligible for this study (374 patients). Those treated with neoadjuvant chemotherapy (66 patients), radiotherapy (15) and patients with positive soft tissue surgical margins were excluded (30). No patient had distant metastases. All patients were considered disease-free after RNU. Death certificates were used to assess cause of death [12] .
Of the 263 patients that met inclusion criteria, 107 (41%) received three to six cycles of AC within 3 months of RNU, while 156 (59%) did not. Three types of cisplatin-based combined chemotherapies were used: methotrexate, vinblastine, adriamycin and cisplatin (MVAC), gemcitabine and cisplatin (GC) or methotrexate, vinblastine, epirubicin and cisplatin (MVEC). No patients received a carboplatinbased chemotherapy. There was no routine restaging after RNU before AC. The treatment protocols and follow-up schedules were surgeon-and institution-dependent. The median (interquartile range, IQR) follow-up for patients alive at last contact was 35 (15-72) months.
Pathological Evaluation
Specimens were processed according to international standards [13] . Tumour grade and stage were re-evaluated by experienced pathologists at each institution according to the 2004 WHO classification system and the 2002 American Joint Cancer Committee (AJCC) TNM system, respectively. Lymphovascular invasion (LVI), tumour architecture, the number of removed LNs and the number of positive LNs were recorded, as described previously [14] . The LN density was calculated and further stratified according to Bolenz et al. [15] .
Statistical Analysis
Categorical variables are shown as numbers and percentages, and continuous variables as medians and IQRs. Group differences in continuous variables and categorical variables were analysed with Kruskal-Wallis tests and chi-square tests, respectively.
Because patients may die from non-UTUC-related causes, Fine and Gray's competing-risks models were used to determine UTUC-related mortality. Death from UTUC was considered the event of interest, while non-UTUC-related death was considered the competing event. Subhazard ratios (SHRs) and 95% CIs were used to describe univariable and multivariable estimates. Group differences were evaluated with Gray's tests. A P value <0.05 was considered to indicate statistical significance. Analyses were all conducted with STATA 12 (College Station, TX, USA).
Results
Characteristics
Of the 263 patients with pathologically positive LNs after RNU, 107 (40.7%) received AC (group 1), while 156 (59.3%) were treated with RNU alone (group 2). Clinical and ª 2014 The Authorspathological characteristics of each group are listed in Table 1 . Patients in group 1 were significantly younger (P < 0.001) and tended to have higher pathological tumour stages (P = 0.06) and LN density (P = 0.054). There were no differences in terms of gender, LVI, tumour architecture, location, grade, and the number of removed and positive LNs.
AC and Mortality
Of the 161 deaths (61%), 144 (89%) were related to UTUC. The 1-, 2-and 5-year UTUC-related mortality rates were 27% (SE 1%), 45% (SE 2%) and 61% (SE 2%), respectively.
In all patients, administration of AC had no significant impact on UTUC-related mortality on univariable analysis (SHR 0.89, P = 0.49, Fig. 1A ). The absolute reduction in mortality was 5% at 1 year, 2% at 2 years, 9% at 3 years, 4% at 4 years, and 7% at 5 years, respectively (Table 2 ). On multivariable analysis that adjusted for the effect of standard prognostic factors, AC had again no significant effect on mortality (P = 0.11). Pathological tumour stage (SHR 3.07, P < 0.001) and the number of LNs removed (SHR 1.05, P = 0.001) and LN density (SHR 1.10, P = 0.002) were the independent prognostic factors ( Table 3) . AC had no impact on disease-free survival (SHR 0.83, P = 0.22).
Subanalyses were performed to identify patients that may benefit from AC (Fig. 2) . Here, administration of AC was associated with a survival benefit in patients with pT3-4 disease. In this subgroup, 92 patients (44%) received AC and 117 (56%) did not. AC reduced the relative risk of UTUCrelated mortality by 34% (SHR 0.66, P = 0.019, Fig. 1B ). The absolute difference in mortality was 10% after the first year and increased to 23% after 5 years (Table 2) . On multivariable analysis, administration of AC was significantly associated with reduced UTUC-related mortality (SHR 0.67, P = 0.022).
Discussion
We retrospectively evaluated the effect of AC on UTUCrelated mortality in patients who had LN metastases after RNU for clinically advanced UTUC. While AC had no effect on outcomes when assessed in all patients, it may be most effective in those with pT3-4 N+. This subgroup of LNpositive patients could serve as target population for an AC trial.
Chemotherapy in UTUC is only recommended as salvage treatment after UTUC recurrence [2] . At present, there is no recommendation for AC, as there are only few retrospective studies with inconsistent findings [16] . In a cohort of 140 patients, Vassilakopoulou et al. [17] found no benefit to AC for overall and cancer-specific survival. Similarly, in a multicentre cohort of 542 patients, Hellenthal et al. [9] showed that AC confers no survival benefit. On the contrary, Raman et al. [10] reported that AC improved cancer-specific survival by 15% (HR 0.85, P = 0.05). In our present study, AC did not reduce UTUC-related mortality for all patients, but only in those at the highest risk for disease recurrence, that is those with pT3-4 N+ disease.
Prospective trials on perioperative chemotherapy in UTUC are lacking. The randomised controlled Peri-Operative chemotherapy vs sUrveillance in upper Tract urothelial cancer (POUT) trial is currently accruing patients [18] . For that study, patients with UTUC staged pT2-pT4 N0-3 M0 or pTany N1-3 M0 after RNU are eligible. The relatively fast recovery after RNU may facilitate inclusion of patients in this trial, although the postoperative decrease in renal function remains a critical issue for administration of cisplatin [19, 20] . For the POUT trial, cisplatin is substituted with carboplatin if the GFR is between 30 and 49 mL/min, but data from bladder cancer indicate that carboplatin has a considerable lower efficacy than cisplatin in UC [21] .
Patient selection for AC remains a critical issue. It is possible that retrospective studies did not show a statistically significant difference due to inclusion of patients at a lower risk for disease recurrence, such as those with N0 disease or with positive LNs at all pathological stages. AC may not be efficient in these groups and studies were underpowered to detect a statistically significant difference. We show that only patients at the highest risk for disease recurrence, i.e. with pT3-4 N+ disease, may benefit from AC. In this subgroup, the relative improvement in mortality was as high as 34%. After 5 years, the UTUC-related mortality rate was 57% for patients treated with RNU and AC, and 80% for those treated with RNU alone. However, AC was used more in pT3 than in pT4 patients, which could reflect selection bias. Prospective randomised trials are necessary. Established prognostic factors, e.g. tumour location, tumour architecture, concomitant carcinoma in situ and LVI, were not significant if associated with outcomes when patients were limited to those with N+ [22] [23] [24] . We therefore hypothesise that in patients with LN-positive disease, these factors are less important for predicting outcomes, and that prognosis is rather driven by pathological tumour stage and the LN density. Postoperative nomograms that combine several prognostic factors have been proposed as helpful tools for selecting patients who could benefit of AC [25] , but further validation studies are required.
The LN status and specifically the LN density may guide decision-making for AC [11, 26] . In our present study, all patients had a LN dissection, which was judged standard or extended according to the individual surgeon, without any standardisation. Unfortunately, we did not have data on clinical N stage, which should be incorporated in future studies and may have an important impact on neoadjuvant protocols and the decision on concomitant LN dissection during RNU. The median number of LNs removed was five, which is similar to other recent series [27] . The impact of a LN dissection on UTUC-related mortality is currently unknown. Patients with ≥pT2 stage seem to benefit most from a LN dissection [11, [28] [29] [30] . In our present study, LN density was an independent prognostic factor, but it did not impact the effect of AC. Further studies on the prognostic role of the LN density in this setting are necessary. Evaluation of LN density can be problematic in retrospective studies, especially when LN dissection is not standardised. Nonetheless, as both the number of removed LNs and the number of positive LNs were prognostically relevant in our present study, it reinforces the concept that the extent of LN dissection may play a prognostic role in UTUC.
The present study has multiple limitations. As UTUC LNpositive disease is rare; the authors had to combine data from multiple international centres over a long study period, resulting in issues about treatment approaches. The retrospective non-randomised design introduced selection bias with an unequal distribution of variables between the two groups. In particular, patients who received AC were younger, had higher tumour stages and LN density, which could have played a role in the choice of a more aggressive treatment after RNU. Multiple factors that may have influenced the clinical decision-making about the use of AC were not collected, such as patient's desire, postoperative renal function, perioperative complications and performance status. Currently, AC after RNU is not recommended in clinical routine [2] . Decisions about AC were dependent on physicians' and patients' choices and depended on multiple factors, such as performance status and pre-and postoperative co-morbidities. The GFR before and after RNU, as well as the presence of chronic kidney disease were not systematically collected, although they are essential in the decision-making process.
Pathological specimens were processed according to international standards, but multiple pathologists were involved without a central review. Further, AC protocols, the exact number of cycles and follow-up were not standardised, although patients who received <3 cycles were excluded. In addition, data on toxicity during AC were not documented in a standardised way and not available for analysis. Finally, no data were available about the site of recurrence, details on concomitant, prior or subsequent bladder cancer, and salvage chemotherapy in cases of recurrence. Nonetheless, our present data suggest that AC is effective in a subgroup of patients with LN-positive UTUC, and that this group should be evaluated in future randomised trials.
In conclusion, AC seems to reduce mortality in patients with pT3-4 LN-positive UTUC after RNU. Appropriately powered prospective randomised trials are necessary to confirm these findings.
1.
Introduction
Radical nephroureterectomy (RNU) with excision of the bladder cuff is the standard of care for high-risk noninvasive and invasive urothelial carcinoma of the upper tract (UTUC) [1] . The outcomes of different bladder cuff management approaches remain poorly investigated [2, 3] . Recently, Li et al. [4] reported no difference in oncologic outcomes among three different approaches of the distal ureter (transvesical, extravesical, and endoscopic) in a retrospective single-center study of 301 patients. This study had a relatively small sample size and short follow-up, limiting its statistical power to assess the impact of distal ureteral management approaches on intravesical recurrence. The aim of the current study was to assess the impact of the three, different, distal ureter management approaches on intravesical recurrencefree survival, recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) in a large, international, multicentric cohort of patients treated with RNU.
Materials and methods
Patients
In this institutional review board-approved study, all participating sites provided necessary institutional data-sharing agreements prior to study initiation. A total of 24 centers worldwide provided data. A computerized databank was generated for data transfer. After combining the data sets, reports were generated for each variable to identify data inconsistencies and other data integrity problems. Through regular communication with all sites, resolution of all identified anomalies was achieved before analysis. Prior to final analysis, the database was frozen and the final data set was produced for the current analysis. In the extravesical technique, the intramural portion of the ureter was completely dissected. With gentle traction on the ureter, a rightangle clamp or stapler was used to transect the distal ureter with its bladder cuff. The bladder was also closed with a two-layer suture.
Surgical technique
In the endoscopic approach, the patient was placed in the lithotomy position and underwent cystoscopy. A resectoscope was inserted into the bladder via the urethra using sterile water for irrigation and the ipsilateral ureteral orifice was endoscopically coagulated. The bladder was kept semidistended to prevent excessive extravasations during the procedure.
A hook electrode was used to incise a circumferential 10-mm cuff of bladder mucosa around the ureteral orifice. Endoscopic-guided dissection and incision deep to the level of perivesical fat and detachment of the intramural ureter were performed. After complete hemostasis, the bladder was catheterized. The patient was repositioned for RNU. The first step of RNU was to identify and ligate the ureter below the level of the tumor prior to mobilizing the kidney. After completing nephrectomy, the distal ureter, including the bladder cuff, was gently retracted and removed. The ureter was checked for complete removal by identifying the coagulated edge of the bladder cuff at the distal ureteral end.
Pathologic analysis
All surgical specimens were processed according to standard pathologic procedures at each institution [5] . Tumors were staged according to the 2002 American Joint Committee on Cancer-Union Internationale Contre le Cancer (AJCC/UICC) TNM classification [6] . Tumor grade was assessed according to the 1998 World Health Organization/International Society of Urologic Pathology consensus classification [7] . Tumor location was defined as either renal pelvic or ureteral [8, 9] . Tumor multifocality was defined as the synchronous presence of two or more pathologically confirmed tumors in any location (renal pelvis or ureter) [10, 11] .
Lymphovascular invasion (LVI) was defined as the presence of tumor cells within an endothelium-lined space without underlying muscular walls [12] .
Follow-up
Patients were followed, generally, every 3-4 mo for the first year following RNU, every 6 mo from the second through the fifth year, and annually thereafter. Follow-up consisted of a history, physical examination, routine ureteral management approaches. Patients who underwent the endoscopic approach were at significantly higher risk of intravesical recurrence compared with those who underwent the transvesical ( p = 0.02) or extravesical approaches ( p = 0.02); the latter two groups did not differ from each other ( p = 0.40). Actuarial intravesical RFS estimates at 2 and 5 yr after RNU were 69% and 58%, 69% and 51%, and 61% and 42% for the transvesical, extravesical, and endoscopic approaches, respectively. In multivariate analyses, distal ureteral management ( p = 0.01), surgical technique (open vs laparoscopic; p = 0.02), previous bladder cancer ( p < 0.001), higher tumor stage (trend; p = 0.01), concomitant carcinoma in situ (CIS) ( p < 0.001), and lymph node involvement (trend; p < 0.001) were all associated with intravesical recurrence. Excluding patients with history of previous bladder cancer, all variables remained independent predictors of intravesical recurrence. Conclusions: The endoscopic approach was associated with higher intravesical recurrence rates. Interestingly, concomitant CIS in the upper tract is a strong predictor of intravesical recurrence after RNU. The association of laparoscopic RNU with intravesical recurrence needs to be further investigated. # 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.
blood work, urinary cytology, chest radiography, cystoscopic evaluation of the urinary bladder, and radiographic evaluation of the contralateral upper urinary tract. Elective bone scans, chest computerized tomography, or magnetic resonance imaging were performed when clinically indicated [13] .
Disease recurrence was defined as tumor relapse in the operative field, regional lymph nodes, and/or distant metastasis; it excluded bladder cancer occurrences. Bladder cancer occurrences were coded as intravesical recurrence. Cause of death was determined by treating physicians, by chart review corroborated by death certificates, or by death certificates alone. To reduce bias in attribution of cause of death, only patients who had UC listed on the death certificate were considered to have died of UTUC for this study [14] . All patients who were coded as dead of cancer had previous disease recurrence. Patients who died in the perioperative period (ie, within 30 d of surgery) were censored at time of death for UTUC-specific survival analyses.
Statistical analysis
Differences in continuous variables across distal ureter management
were assessed using the Kruskal-Wallis test. The chi-square test was used to evaluate the association between categorical variables and the three procedures (transvesical, extravesical, and endoscopic). RFS, intravesical RFS, CSS, and OS curves were generated using the KaplanMeier method and compared using the log-rank test. Univariable and multivariable Cox regression models addressed outcomes after RNU. 
Results
Association between distal ureteral management and clinicopathologic characteristics in all patients
Of the 2681 patients, 1811 (67.5%) underwent the transvesical approach, 785 (29.3%) underwent the extravesical approach, and 85 (3.2%) underwent the endoscopic approach. Endoscopic management was performed at eight institutions (2 to 54 cases per institution). The distribution of clinicopathologic features and their association with distal ureteral management is shown in Table 1 . Compared to patients who underwent the transvesical or extravesical approaches, those who underwent the endoscopic approach were more likely to have been treated using laparoscopic RNU ( p < .01) and to harbor pelvicaliceal tumors ( p < .01), and less likely to exhibit tumor multifocality ( p .02).
Association between distal ureteral management and clinical outcomes in all patients
The median follow-up in patients alive at last follow-up was 57.5 mo (range: 1-271 mo). Disease recurrence occurred in 748 patients (27.9%), while intravesical recurrence occurred in 577 patients (21.5%); 605 patients (22.6%) died of UTUC, and 966 patients (36%) died of any cause. Actuarial RFS estimates at 2 and 5 yr after RNU were 71% and 66%, 73% and 66%, and 77% and 69% for the transvesical, extravesical, and endoscopic approaches, respectively (Fig. 1) . Actuarial CSS
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Fig. 1 -Recurrence-free survival. SE = standard error.
estimates at 2 and 5 yr after RNU were 80% and 71%, 79% and 70%, and 82% and 82% for the transvesical, extravesical, and endoscopic approaches, respectively. Actuarial OS estimates at 2 and 5 yr after RNU were 71% and 66%, 73% and 66%, and 77% and 69% for the transvesical, extravesical, and endoscopic approaches, respectively. Actuarial intravesical RFS estimates at 2 and 5 yr after RNU were 69% and 58%, 69% and 51%, and 61% and 42% for the transvesical, extravesical, and endoscopic approaches, respectively (Fig. 2a) . In multivariable Cox regression analysis, endoscopic distal ureter management, male sex, laparoscopic surgical technique, previous bladder cancer, higher tumor stage, concomitant carcinoma in situ (CIS), and lymph node involvement were all associated with intravesical recurrence ( 
chemotherapy did not change the statistical significance of the variables except for tumor stage, which became nonsignificant, and female sex, which became significant. Subgroup analyses in patients who underwent laparoscopic RNU and those who underwent open RNU showed similar results (data not shown).
3.3.
Association between distal ureter management and clinical outcomes in patients without previous bladder cancer
When excluding patients with a history of previous bladder cancer, actuarial intravesical RFS estimates at 2 and 5 yr after RNU were 81% and 71%, 84% and 64%, and 62% and 40% 
for the transvesical, extravesical, and endoscopic approaches, respectively (Fig. 2b) . Endoscopic distal ureter management, concomitant CIS, lymph node involvement, higher tumor stage, and laparoscopic surgical technique remained independent predictors of intravesical recurrence (Table 2) .
Matched-pair comparative analysis
We performed a matched-pair comparative analysis based on the 85 patients who underwent endoscopic distal ureter management on a 3:1 model (n = 595 patients 
Discussion
No difference in RFS, CSS, and OS was reported between patients managed with either transvesical, extravesical, or endoscopic bladder cuff approach. Total excision of the distal ureter with its intramural portion, the ipsilateral ureteral orifice, and bladder cuff is necessary for optimal management of UTUC [2, 15] . While the transvesical approach has been the standard for ensuring complete bladder cuff excision, several newer techniques, such as transurethral resection of the intramural ureter, intussusception techniques, and stripping, have been described to simplify resection of the distal ureter [16] . Apart from ureteral stripping, these novel techniques have been shown to be not inferior to the transvesical approach, albeit the follow-up of these studies was too short to make definitive conclusions, specifically with regard to intravesical recurrence. Indeed, studies have reported the risk of tumor recurrence within the residual ureteral stump/periureteral meatal region in cases of incomplete bladder cuff removal to be 30-64% [17] [18] [19] [20] [21] . While RFS and CSS are major end points in patients treated with RNU for UTUC, intravesical recurrence is a significant, yet underevaluated, end point to be considered in decision making regarding the optimal treatment and follow-up for UTUC patients. We found that endoscopic management of the distal ureter results in significantly higher intravesical recurrence rates as compared to the transvesical or extravesical approaches. This association was independent when adjusted for the effect of established outcome predictors in UTUC and remained even after exclusion of patients with past history of non-muscle-invasive bladder cancer. Possible causes for the higher rate of intravesical recurrence in patients treated with the endoscopic approach include tumor spillage and/or incomplete tumor removal. This is in contrast to Li et al, who reported no difference in intravesical recurrence rates among the three approaches [4] . Conclusions from the Li et al. study were limited by the small sample size, short follow-up, low number of events, and single-center nature of their study. Conversely, our study suffered from heterogeneity in management and selection of patients, imbalance in the type of ureteral management technique between centers, and unadjusted biases inherent to retrospective studies.
We found a higher, but not statistically significantly different, rate of late intravesical recurrence in patients who underwent an extravesical approach (either stapling or clamping) compared with those who underwent a transvesical approach. The blind extravesical stapling or clamping does not inevitably guarantee adequate bladder cuff retrieval [3, 21] . Patients treated with the extravesical approach had a higher rate of laparoscopic RNU and adjuvant chemotherapy and those with a transvesical approach had a higher rate of non-muscle-invasive UTUC and previous bladder cancer. The failure to reach statistical significance could be due to the relatively short follow-up time and biases inherent to retrospective studies, such as patient selection. The transvesical approach is not without pitfalls either. For example, an anterior cystotomy must be avoided in the presence of active bladder UC as it retains the potential to seed tumor into the extravesical space. Moreover, early ligation/clipping of the ureter during the nephrectomy seems theoretically preferential. In addition, prior pelvic surgery or irradiation and obesity may render the open procedure more challenging. Notwithstanding these potential concerns, the transvesical approach to distal ureter removal is not only oncologically sound, it has withstood the test of time [16] . While the absolute intravesical recurrence rate was different between the transvesical and extravesical approaches, based on the statistical analyses, we found no difference in any of the outcomes between these approaches. We found that, in addition to distal ureteral approach, features of disease stage (T stage and lymph node involvement), male sex, laparoscopic surgical approach, concomitant CIS, and history of previous non-muscle-invasive bladder cancer were independent predictors of intravesical recurrence. Exclusion of patients with previous bladder cancer did not change the association of the other predictors except sex. Concomitant CIS in the bladder has been associated with UTUC development [22] . In RNU patients with organ-confined UTUC, concomitant CIS has been shown to be a predictor of disease recurrence and CSS [23, 24] . One single study to date reported that concomitant CIS is associated with intravesical recurrence [25] . We found that laparoscopic RNU is associated with a higher risk of intravesical recurrence compared with open RNU. In contrast, Favaretto et al. did not find any difference in the rate of intravesical recurrence between laparoscopic and open RNU in a relatively smaller (324 patients) single-center study [26] . In our study, most patients who underwent endoscopic resection of bladder cuff also had concomitant laparoscopic surgery, thereby, perhaps, confounding the impact of laparoscopic surgery on intravesical recurrence. Moreover, several studies reported no difference in nonbladder recurrence and survival between laparoscopic and open RNU, provided there was adherence to the same oncologic principles [26] [27] [28] . Certainly, future studies have to assess the differential effect of minimal invasive RNU on intravesical recurrence.
The current study suffers from several limitations. First and foremost are the limitations inherent to retrospective multicentric study design. We did not perform a centralized pathologic review, which could have led to misinterpretations of pathologic specimens and underreporting of features such as concomitant CIS. In addition, small differences in surgical technique not captured by our data may have profound effects on the measured outcomes. Furthermore, differences in the postoperative follow-up of the bladder between participating centers may have affected outcomes. Moreover, immediate, postoperative, single, intraoperative chemotherapy may lower the intravesical recurrence rate, thereby abrogating the effects seen in our study [29] . Finally, information on complications, operative time, blood loss, and recovery were not available in our multicenter database and this information could balance our findings.
Conclusions
While there are no differences in nonbladder recurrence and survival between transvesical, extravesical, and endoscopic management of the bladder cuff, the endoscopic approach results in higher intravesical bladder cancer recurrences. Concomitant CIS of the upper tract is a strong predictor of intravesical recurrence after RNU. After further validation, a risk-based follow-up strategy needs to be developed to determine follow-up scheduling (ie, cystoscopy) and management.
Author contributions: Shahrokh F. Shariat had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Xylinas, Shariat. Analysis and interpretation of data: None.
Drafting of the manuscript: Xylinas, Rink, Cha, Shariat.
Critical revision of the manuscript for important intellectual content:
Fritsche, Raman, Lotan, Matsumoto, Walton, Matin, Novara, Zerbib.
Statistical analysis: Clozel, Lee, Shariat.
Obtaining funding: None.
Administrative, technical, or material support: None.
Supervision: Shariat.
Other (specify): None.
Financial disclosures: Shahrokh F. Shariat certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.
Funding/Support and role of the sponsor: None.
